LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases - Top-Institutions - MDSpire

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases

  • By

  • Genshan Zhang

  • Wei Jiang

  • Fangxun He

  • Jie Fu

  • Xiangshang Xu

  • Xuelai Luo

  • Zhixin Cao

  • April 18, 2024

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Genomic Medicine
    • Cardiovascular Research
    • Metabolic Disease

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Hepatology
    • Clinical Trials

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Cardiovascular Medicine
    • Genetics
    • Hepatology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Hepatology
    • Cardiology
    • Genomic Medicine

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Hepatology
    • Metabolic Disease

Original Source(s)

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases

  • by Genshan Zhang, Wei Jiang, Fangxun He, Jie Fu, Xiangshang Xu, Xuelai Luo, Zhixin Cao

  • April 18, 2024

Related Content

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.